Accredo Health Inc. (ACDO) Selected By CoTherix, Inc. (CTRX) For Ventavis Distribution
10/19/2005 5:12:31 PM
MEMPHIS, Tenn.--(BUSINESS WIRE)--Jan. 19, 2005--Accredo Health, Incorporated (NASDAQ: ACDO) announced today that one of its three primary divisions, Accredo Therapeutics, has been selected by CoTherix, Inc. (NASDAQ: CTRX) as one of up to three specialty pharmacy providers of Ventavis(TM) (iloprost) Inhalation Solution. Ventavis, which was recently approved by the FDA for the treatment of pulmonary arterial hypertension (World Health Organization Group I), or PAH, in patients with New York Heart Association Class III or IV symptoms. Ventavis is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins (naturally occurring molecules that cause blood vessels to dilate). PAH is a highly debilitating disease characterized by severe constriction of the blood vessels of the lungs.